Inactive Instrument

Bruker Cellular Analysis, Inc.

Equities

BLI

US0843101017

Biotechnology & Medical Research

PhenomeX Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 12, 2023 at 01:36 am IST

PhenomeX Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported revenue was USD 18.52 million compared to USD 20.21 million a year ago. Net loss was USD 23.42 million compared to USD 21.43 million a year ago.

Basic loss per share from continuing operations was USD 0.31 compared to USD 0.32 a year ago.

Latest news about Bruker Cellular Analysis, Inc.

PhenomeX Inc Announces Board Changes	02/23/02	CI
PhenomeX Inc. has Changed its Name to Bruker Cellular Analysis, Inc	02/23/02	CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from NASDAQ Composite Index	02/23/02	CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from S&P TMI Index	02/23/02	CI
Bruker Corporation completed the acquisition of PhenomeX Inc..	29/23/29	CI
Phenomex Announces Opto Memory B Discovery Human Workflow on the Beacon®? Optofluidic Platform	27/23/27	CI
PhenomeX Inc. Announces the Release of SpotLight? Human Lambda Reagent for the Beacon® Platform to Accelerate Cell Line Development Workflows	21/23/21	CI
PhenomeX Inc.(NasdaqGS:CELL) dropped from S&P Global BMI Index	18/23/18	CI
Phenomex Unveils Meteor Chips for Quantitative Bulk Analysis on the Isospark? Platform to Revolutionize High Throughput Multiplexed Hands-Free Proteomics	15/23/15	CI
North American Morning Briefing : Nasdaq Futures -2-	24/23/24	DJ
TD Cowen Downgrades PhenomeX to Market Perform From Outperform, Price Target is $1	23/23/23	MT
North American Morning Briefing : Nvidia Results -2-	23/23/23	DJ
Berenberg Downgrades PhenomeX to Hold From Buy, Adjusts Price Target to $1 From $8	22/23/22	MT
North American Morning Briefing : Focus Shifts to -2-	21/23/21	DJ
Morgan Stanley Upgrades PhenomeX to Equalweight From Underweight, Adjusts Price Target to $1 From $5	18/23/18	MT
Bruker to Acquire PhenomeX in $108 Million All-Cash Deal	17/23/17	MT
Bruker Corp & Phenomex Inc Announce Agreement For Bruker To Acquire Phenomex In All-Cash Transaction	17/23/17	RE
Bruker Corporation signed a definitive agreement to acquire all of the outstanding shares of PhenomeX Inc..	17/23/17	CI
Berenberg Bank Adjusts PhenomeX Price Target to $8 From $9, Maintains Buy Rating	15/23/15	MT
Earnings Flash (CELL) PHENOMEX Posts Q2 Revenue $14.1M, vs. Street Est of $17.4M	15/23/15	MT
Earnings Flash (CELL) PHENOMEX Posts Q2 Revenue $14.1M, vs. Street Est of $17.4M	15/23/15	MT
PhenomeX Inc. Announces Impairment of Goodwill for the Second Quarter Ended June 30, 2023	15/23/15	CI
PhenomeX Inc. Reiterates Earning Guidance for the Full Year of 2023	15/23/15	CI
PhenomeX Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	15/23/15	CI
Phenomex Board Launches A Process to Explore, Review, Evaluate A Range of Potential Strategic Alternatives	08/23/08	CI

Chart Bruker Cellular Analysis, Inc.

Duration

Period

More charts

Company Profile

PhenomeX Inc., formerly Berkeley Lights, Inc., is a functional cell biology company. The Company enables scientists to leverage each cell and drive the next generation of functional cell biology that will advance human health. The Company enables scientists to reveal insights into cell function and obtain a full view of the behavior of each cell. Its specific suite of proven tools and services offers unparalleled resolution and speed the insights that are key to advancing discoveries that can completely improve the prevention and treatment of disease. The Company's platforms are used by researchers across the globe, including various global pharmaceutical companies and approximately 85% of United States cancer centers.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
MODERNA, INC.	+33.37%	49.46B
IQVIA HOLDINGS INC.	+1.55%	42.58B
LONZA GROUP AG	+49.11%	42.49B
CELLTRION, INC.	-4.22%	29.09B
ICON PUBLIC LIMITED COMPANY	+11.57%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-21.00%	18.64B
BIO-TECHNE CORPORATION	+7.36%	13.16B
MEDPACE HOLDINGS, INC.	+28.30%	12.55B
UNITED THERAPEUTICS CORPORATION	+23.80%	12.1B

Other Biotechnology & Medical Research